Bleomycin A5 (cas 11116-32-8) sclerotherapy for cervicofacial lymphatic malformations
-
Add time:07/19/2019 Source:sciencedirect.com
ObjectivesThe purpose of this study was to document the results of Bleomycin A5 (cas 11116-32-8) sclerotherapy for cervicofacial lymphatic malformations (LMs), and the clinical data of 65 patients between October 2004 and October 2007 were reviewed.
We also recommend Trading Suppliers and Manufacturers of Bleomycin A5 (cas 11116-32-8). Pls Click Website Link as below: cas 11116-32-8 suppliers
Prev:How to use Bleomycin A5 (cas 11116-32-8) for infantile maxillofacial haemangiomas: Clinical evaluation of 82 consecutive cases
Next:Bleomycin A5 (cas 11116-32-8) plus dexamethasone for control of growth in infantile parotid hemangiomas) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma07/23/2019
- A clinical study of ultrasound-guided intralesional injection of Bleomycin A5 (cas 11116-32-8) on venous malformation in cervical-facial region in China07/22/2019
- Electrophoresis mobility shift assay and biosensor used in studying the interaction between Bleomycin A5 (cas 11116-32-8) and DNA07/20/2019
- Bleomycin A5 (cas 11116-32-8) plus dexamethasone for control of growth in infantile parotid hemangiomas07/21/2019
- How to use Bleomycin A5 (cas 11116-32-8) for infantile maxillofacial haemangiomas: Clinical evaluation of 82 consecutive cases07/18/2019
-
Health and Chemical more >